Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database-Reference-Cited by-同舟云学术

Characteristics and risk differences of different tumor sizes on distant metastases of hepatocellular carcinoma: A retrospective cohort study in the SEER database

Published:2020-08 Issue: Volume:80 Page:94-100
ISSN:1743-9191
Container-title:International Journal of Surgery
language:en
Short-container-title:International Journal of Surgery

Author:

Yan Bing,Bai Dou-Sheng,Zhang Chi,Qian Jian-Jun,Jin Sheng-Jie,Jiang Guo-Qing

Funder

Jiangsu Provincial Medical Youth Talent

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference29 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA. Cancer J. Clin.,2018

2. Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: analyzing patterns of progression in 285 patients;Senthilnathan;Hepatology,2012

3. Clinical features of hepatocellular carcinoma with extrahepatic metastases;Natsuizaka;J. Gastroenterol. Hepatol.,2005

4. Extrahepatic metastasis of hepatocellular carcinoma: incidence and risk factors;Kanda;Liver Int.,2008

5. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors;Uchino;Cancer,2011

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for measuring tumor size of solitary hepatocellular carcinoma ≤ 5cm: A real-world study;2024-09-11

2. Leveraging SEER data through machine learning to predict distant lymph node metastasis and prognosticate outcomes in hepatocellular carcinoma patients;The Journal of Gene Medicine;2024-08-26

3. Characteristics and risk differences of different tumor sizes on distant metastases of pancreatic neuroendocrine tumors: A retrospective study in the SEER database;Hepatobiliary & Pancreatic Diseases International;2024-07

4. Survival Benefit of Synchronous Lenvatinib Combined PD-1 Inhibitors for Advanced Hepatocellular Carcinoma Beyond Oligometastasis;ImmunoTargets and Therapy;2024-06

5. Transarterial Chemoembolization (TACE) Combined with Lenvatinib versus TACE Alone in Intermediate-Stage Hepatocellular Carcinoma Patients Beyond Up-To-Seven Criteria: A Retrospective, Propensity Score-Matched Analysis;Academic Radiology;2024-05